RenalytixAI to Participate in the Stifel 2020 Healthcare Conference

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference.

RenalytixAI’s management is scheduled to present on Tuesday, November 17 at 10:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at www.investors.renalytixai.com.

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI’s products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com.

Disclosure Information

Renalytix AI plc uses filings with the Securities and Exchange Commission, its website (www.renalytixai.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Investor
Contact
:

[email protected]

Ærfugl phase 1 project starts production

PR Newswire

TRONDHEIM, Norway, Nov. 13, 2020 /PRNewswire/ —

Operator Aker BP and partners Equinor, Wintershall Dea and PGNiG report that production has started from Ærfugl phase 1 in the Norwegian Sea.

– I am very proud of the excellent performance shown by the Aker BP project team and our alliance partners to deliver this profitable project safely and efficiently on time and cost. This truly is One Team at its best, says CEO in Aker BP, Karl Johnny Hersvik. 

Ærfugl is one of the most profitable development projects on the Norwegian continental shelf. The initial estimated break-even oil price was USD 18.5 per barrel (converted from gas). Due to increased reserves, earlier production, stronger dollar and accelerated tax depreciation, the break-even price has improved to below USD 15 per barrel.

– Aker BP’s goal is to produce oil and gas as efficiently as possible to return greater value from our oil and gas resources to investors and the society. The successful start-up of production from Ærfugl phase 1 demonstrates our ability to deliver on this strategy, Hersvik adds.

300 million barrels

The Ærfugl development is a major subsea project in two phases. Both phases are tied into the existing production vessel (FPSO) on the Skarv field, which is located approx. 210 km west of Sandnessjøen.

The Plan for Development and Operation (PDO) for Ærfugl was approved by the Ministry of Petroleum and Energy in April 2018.

The reservoir holds a total of around 300 million barrels of producible oil equivalents. 

Total investment costs for the Ærfugl project (phase 1 and 2) are around NOK 8 billion.

Improvements

Reorganizing the value chain through strategic partnerships and alliances is an important part of Aker BP’s strategy.

-The subsea alliance, semi alliance and modification alliance have all been vital in this project. The alliances have not only been delivering on cost and schedule, despite Covid-19 related challenges; they have as well achieved major improvements since the PDO was approved, including significantly accelerated development of phase 2 and better economics, says SVP Projects, Knut Sandvik.

Development of Ærfugl is enabled in particular by two new technologies:           

  • More efficient drainage of reservoir through new vertical valve trees.            
  • Long distance, electrically heated flow lines to avoid hydrates in the gas pipelines. This technology significantly improves heat efficiency compared with regular technology and enables longer tie-backs. 

Reserves have as well increased since PDO due to continuous work to better understand the elongated reservoir.

Strengthening the Skarv area

The Ærfugl field development is adding five years lifetime extension to the Skarv FPSO.

-Ærfugl is an important part of the area development and value creation in the area. When both phases of Ærfugl come on stream, we will significantly increase our utilization at the Skarv FPSO, representing roughly a doubling of production compared to current levels, says Sverre Isak Bjørn, VP Operations & Asset Development, Skarv area.

-Production from the Ærfugl reservoir will also improve the energy efficiency. Consequently it will bring down CO2 emissions by 30-40% per barrel produced from Skarv FPSO, Bjørn adds.

Exploration success in the area in 2019 gave fresh perspectives on the geology around Skarv, generating new ideas on drilling prospects in the coming years. 

-We are collaborating closely with our license partners. Together we have developed a solid strategic foundation to bring Skarv into the future, Bjørn adds.

Full speed for Phase 2

Phase 1, which develops the southern part of the Ærfugl field, consists of three new wells. Phase 2 consists of an additional three wells in the northern part of the field.

-The successful start-up of production from Phase 1 is a major milestone and a great achievement. However, there is no time to relax; we will keep momentum to safely deliver phase 2 on time and cost by the end of next year. Then we will celebrate, says Project manager for the Ærfugl development project, Tom Storvik

He points at the close and efficient collaboration in- and between the involved alliances as a key success factor for the successful execution.

-The Subsea alliance between Aker BP, Subsea 7 and Aker Solutions has demonstrated substantial improvements and increased value creation over several years. The performance by the rig alliance with Odfjell and Halliburton and the Modification alliance with Aker Solutions in collaboration with Kongsberg Maritime, has been key to these achievements. The production start-up of from Phase 1 shows how the alliances enable us to increase the value creation and to deliver in line with our ambitious improvement agenda, Storvik adds.

FACTS ABOUT THE ÆRFUGL FIELD            

  • The more than 60 km long and 2-3 km wide Ærfugl reservoir is a gas reservoir.            
  • It holds a total of around 300 million barrels of producible oil equivalents.           
  • Total investment costs for the Ærfugl project (phase 1 and 2) are around NOK 8 billion.            
  • The total `life of field’ project has a break-even-price of below USD 15 per barrel (converted from gas). This makes the field development one of the most profitable being implemented on the Norwegian shelf.            
  • Ærfugl was first put on stream with the test producer A-1H in 2013 and has since produced via Skarv FPSO.           
  • In April this year, production started from the first Ærfugl phase 2 well – more than three years ahead of the original plan.            
  • The remaining two “phase 2 wells” will come on stream in 2021.The Ærfugl field produces via Skarv FPSO approximately 210 km west of Sandnessjøen.           
  • The subsea modules have been completed in Sandnessjøen and then transported offshore. The Ærfugl project has brought significant local ripple effects for local suppliers in the Helgeland region.

CONTACT:

Contacts:

Investor contact: Kjetil Bakken, VP Investor Relations, tel.: +47 918 89 889
Media contact: Ole-Johan Faret, Press Spokesman, tel.: +47 402 24 217

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/aker-bp-asa/r/aerfugl-phase-1-project-starts-production,c3236392

The following files are available for download:

Cision View original content:http://www.prnewswire.com/news-releases/aerfugl-phase-1-project-starts-production-301172568.html

SOURCE Aker BP ASA

CooTek to Participate in November Investor Conferences

PR Newswire

SHANGHAI, Nov. 13, 2020 /PRNewswire/ — CooTek (Cayman) Inc. (NYSE: CTK) (“CooTek” or the “Company”), a fast-growing global mobile internet company, today announced that the Company will present and meet with institutional investors at the following virtual investor conferences. For more information on CooTek presentations, please visit investor relations website https://ir.cootek.com.

  • BofA Securities 2020 China Conference
    Panel or one-on-one Discussion on November 2 – November 13, 2020;
  • dbVIC – Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference
    Presentation on Wednesday, November 18, 2020 at 09:30 a.m. ET

The Company’s management will participate in virtual meetings with institutional investors throughout these events. For additional information, please contact your respective institutional sales representative at each sponsoring bank.

About CooTek (Cayman) Inc.

CooTek is a fast-growing mobile internet company with a global vision, offering mobile applications. Our mission is to empower everyone to enjoy relevant content seamlessly. The Company’s user-centric and data-driven approach has enabled it to release appealing products to capture mobile internet users’ ever-evolving content needs and helps it rapidly attract targeted users. CooTek has developed and brought to market content-rich mobile applications, focusing on three categories: online literature, scenario-based content apps and casual games.

For more information on CooTek, please visit https://ir.cootek.com.  

For more information, please contact:

CooTek (Cayman) Inc.

Mr. Robert Cui
[email protected]  

Christensen

In China
Mr. Rene Vanguestaine
Phone: +86-10-5900-1548
E-mail: [email protected]   
In U.S.
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: [email protected]

Cision View original content:http://www.prnewswire.com/news-releases/cootek-to-participate-in-november-investor-conferences-301172564.html

SOURCE CooTek

Sanofi selects Jeito Capital as its first investment into a private French-based fund

Sanofi selects Jeito Capital as its first investment into a private French-based fund

Paris, France, 13 November 2020 – Jeito Capital (“Jeito”), a rapidly emerging independent investor dedicated to biotech and biopharma, today announced that Sanofi has made a €50 million investment in Jeito Capital. The investment will be deployed by Jeito’s highly experienced team of pharmaceutical and biotech experts in line with its investment criteria to provide an additional gateway for Sanofi to support French and European healthcare innovation. The coming together of a leader in industry with a leading investor will strengthen the ever-important healthcare eco-system and accelerate access to therapeutic innovation.

Rafaèle Tordjman, Founder and CEO at Jeito, said:
“We are delighted that Sanofi chose to become a major strategic investor in Jeito. Receiving such support from one of the global leaders in healthcare and France’s largest R&D investor underlines Jeito’s commitment to improving healthcare in France and Europe. By bringing together industry and science and providing access to significant capital, Jeito is ideally positioned to deliver on its mission to improve healthcare for patients in France and beyond.”

Paul Hudson, CEO of Sanofi, said:
“We are pleased to collaborate with Jeito Capital and its international team of pharma and biotech experts who are renowned for creating value through innovation. This investment provides Sanofi with access to the very best in French and European healthcare innovation and reinforces our commitment to investing in our medium and long-term development pipeline. We strongly believe in the potential of France and Europe to become a world-class hub for innovation in life sciences, which just needs the appropriate conditions and a stimulating environment in order to thrive.”

Jeito’s unique investment strategy is to provide long-term strategic support to new and established entrepreneurs, primarily in France and Europe, who are aspiring to help patients in need by pioneering novel, groundbreaking medicines that rethink traditional approaches. Leveraging their synergistic experience, Jeito’s team provides continuity from clinical development to market access, especially in Europe and the Unites States, for breakthrough drugs with validated proofs of concept. This continuity is expressed both in the support provided to entrepreneurs by the Jeito team and by the investment of significant capital to ensure the growth of companies, the acceleration towards commercialization and faster access to these major innovations.

This investment is part of Sanofi’s leading contribution to the development of an innovative healthcare eco-system in France and Europe. The company previously collaborated with Bpifrance to launch two public-private investment funds dedicated to French and European life sciences. Sanofi also stands as France’s leading private R&D investor, with more than €2 billion spent locally each year researching new treatments for patients, totaling half of the private research effort in France. Nearly 5,000 researchers and scientists work in a variety of therapeutic areas, mainly focusing on oncology, immuno-oncology, vaccines and rare diseases.

ENDS

About Jeito Capital

Jeito Capital is an international investment company with a patient benefit driven approach that focuses both on financing ground-breaking medical innovation and promoting positive societal impact. Jeito has a unique, long-term investment strategy, with the aim of providing continuity from clinical development to market access for breakthrough drugs with validated proofs of concept. This continuity is expressed both in the support provided to entrepreneurs by the Jeito Capital team and by the investment of significant capital to ensure the growth of companies, the acceleration towards commercialization and faster access to these major innovations.  Jeito Capital is based in Paris with a presence in Europe and the United States.  

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, and provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

For more information please contact:

Jeito Capital

Rafaèle Tordjman, Founder and CEO

[email protected]

Consilium Strategic Communications

Mary-Jane Elliott / Melissa Gardiner / Kris Lam

[email protected]

Steele & Holt (France)

Servane Taslé : [email protected]

Anaïs Miegeville : [email protected]

Sanofi

Chrystel Baude : [email protected]

 

Tel: +33 6 35 36 35 00

 

 

Tel: +44 (0) 20 3709 5700

 

 

 

Tel: +33 6 66 58 84 28

Tel: +33 6 33 73 85 16

 

Tel: +33 1 53 77 46 46

ObsEva SA to present at Jefferies Virtual London Healthcare Conference, November 17 – 19, 2020

Geneva, Switzerland and Boston, MA – November 13, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health today announced that Company Management will present an update on the Company and its pipeline at the 11th Annual Jefferies (Virtual) London Healthcare Conference, taking place November 17 – 19, 2020.

ObsEva’s presentation will take place on Wednesday November 18 at 12:55 p.m. Greenwich Mean Time (GMT).  A live presentation link will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan,” “potential,” “will,” and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, clinical development and related interactions with regulators, , ObsEva’s reliance on third parties over which it may not always have full control, the impact of the novel coronavirus outbreak, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2019, the Risk Factors disclosed in ObsEva’s Report on Form 6-K filed with the Securities and Exchange Commission (SEC) on November 5, 2020 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

CEO Office contact

Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

 

 

 

Attachment

Kiadis announces presentations at the 2020 ASH Annual Meeting and Exposition

Amsterdam, The Netherlands, November 13, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative NK-cell-based medicines for the treatment of life-threatening diseases, today announces that five abstracts related to its K-NK-cell therapy platform were accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually from December 5-8, 2020.

The ASH abstracts are now available online through the ASH conference website at www.hematology.org/Annual-Meeting/Abstracts/.

Details of the oral presentation are as follows:

  • Oral Presentation #68: Haploidentical MbIL-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia
    Presenter: Piyanuch Kongtim, MD
    Affiliation: MD Anderson Cancer Center, Houston, TX
    Session: 704. Immunotherapies: Beyond T to NK
    Presentation Date: Saturday, December 5, 2020: 8:45 AM

Details of the poster presentations are as follows:

  • Poster #825: Optimizing Ex-vivo Expanded NK Cell- Mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) Combined With NKTR-255 in Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), and Burkitt Lymphoma (BL)
    Presenter: Yaya Chu
    Affiliation: New York Medical College, Valhalla, NY
    Session: 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Poster I
    Presentation Date: Saturday, December 5, 2020: 7:00 AM-3:30 PM Poster Hall
  • Poster #2151: A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy
    Presenter: Lindsay Rein, MD
    Affiliation: Duke University Medical Center, Durham, NC
    Session: 632. Chronic Myeloid Leukemia: Therapy: Poster II
    Presentation Date: Sunday, December 6, 2020: 7:00 AM-3:30 PM, Poster Hall
  • Poster #2341: BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)
    Presenter: Sumithira Vasu, MD
    Affiliation: The Ohio State University, Columbus, OH
    Session: 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Poster II
    Presentation Date: Sunday, December 6, 2020: 7:00 AM-3:30 PM, Poster Hall
  • Poster #2347: A Phase I Clinical Trial Testing the Safety of IL-21-Expanded, Off-the-Shelf, Third-Party Natural Killer Cells for Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Presenter: Sumithira Vasu
    Affiliation: The Ohio State University, Columbus, OH
    Session: 704. Immunotherapies: Poster II
    Presentation Date: Sunday, December 6, 2020: 7:00 AM-3:30 PM, Poster Hall

Dutch Translation/Nederlandse vertaling


Kiadis Pharma N.V.

(“Kiadis”) is een Nederlands beursgenoteerd biotechbedrijf in de klinische fase dat nieuwe geneesmiddelen ontwikkelt tegen ernstige ziekten. Het maakt daarbij gebruik van Natural Killer-cellen (NK-cellen), grote witte bloedlichamen die de eerste verdedigingslinie in het menselijk afweersysteem vormen tegen kankercellen en infecties. Kiadis maakt dat vijf ‘abstracts’ over het K-NK-celtherapieplatform zijn geaccepteerd voor presentatie op de 62e American Society of Hematology (ASH) Annual Meeting and Exposition die virtueel wordt gehouden van 5 tot 8 december 2020.

De ASH-samenvattingen zijn nu online beschikbaar via de ASH-conferentiewebsite op www.hematology.org/Annual-Meeting/Abstracts/.

Details van de presentaties zijn als volgt:

  • Poster #2151: Een fase I-onderzoek naar het opnemen van Natural Killer-cellen (K-NK) voor patiënten met chronische myeloïde leukemie (CML) en moleculaire restziekte na therapie met tyrosinekinaseremmers (TKI)
    Presentator: Lindsay Rein, MD
    Gelieerd aan: Duke University Medical Center, Durham, NC
    Sessie: 632. Chronische myeloïde leukemie: therapie: poster II
    Presentatiedatum: zondag 6 december 2020: 7:00 – 15:30 uur, Posterzaal
  • Mondelinge presentatie #68: Haplo-identieke MbIL-21 ex vivo geëxpandeerde NK-cellen (FC21-NK) voor patiënten met meervoudige recidiverende en refractaire acute myeloïde leukemie
    Presentator: Piyanuch Kongtim, MD
    Gelieerd aan: MD Anderson Cancer Center, Houston, TX
    Sessie: 704. Immuuntherapie: voorbij T tot NK
    Presentatiedatum: zaterdag 5 december 2020: 8.45 uur
  • Poster #825: Optimalisatie van ex-vivo geëxpandeerde NK-celgemedieerde antilichaamafhankelijke cellulaire cytotoxiciteit (ADCC) gecombineerd met NKTR-255 bij chronische lymfatische leukemie (CLL), folliculair lymfoom (FL) en Burkitt lymfoom (BL)
    Presentator: Yaya Chu
    Gelieerd aan: New York Medical College, Valhalla, NY
    Sessie: 203. Lymfocyten, lymfocytactivering en immunodeficiëntie, inclusief hiv en andere infecties: poster I
    Presentatiedatum: zaterdag 5 december 2020: 07:00 – 15:30 uur Posterzaal
  • Poster #2341: BMT CTN 1803: Haploidentical Natural Killer Cells (K-NK002) ter voorkoming van terugval na transplantatie bij AML en MDS (NK-REALM)
    Presentator: Sumithira Vasu, MD
    Gelieerd aan: The Ohio State University, Columbus, OH
    Sessie: 703. Adoptieve immunotherapie: mechanismen en nieuwe benaderingen: poster II
    Presentatiedatum: zondag 6 december 2020: 7:00 – 15:30 uur, Posterzaal
  • Poster #2347: Een fase I klinisch onderzoek naar de veiligheid van IL-21-uitgebreide, off-the-shelf natural killer-cellen van derden voor recidiverende/refractaire acute myeloïde leukemie en myelodysplastisch syndroom
    Presentator: Sumithira Vasu
    Gelieerd aan: The Ohio State University, Columbus, OH
    Sessie: 704. Immuuntherapie: Poster II
    Presentatiedatum: zondag 6 december 2020: 7:00 – 15:30 uur, Posterzaal

Dit persbericht vormt een samenvatting van het gepubliceerde Engelstalige persbericht. Bij eventuele verschillen is de tekst van het Engelstalige persbericht altijd leidend.

Contacts

Kiadis:

Maryann Cimino, Sr. Manager, Corporate Affairs
Tel: +1 (617) 710-7305
[email protected]

 

LifeSpring Life Sciences Communication:

Leon Melens (Amsterdam)
Tel: +31 538 16 427
[email protected]

Optimum Strategic Communications:
Mary Clark, Supriya Mathur
Tel: +44 203 950 9144
[email protected]

About Kiadis

Founded in 1997, Kiadis is building a fully integrated biopharmaceutical company committed to developing innovative cell-based medicines for patients with life-threatening diseases. With headquarters in Amsterdam, The Netherlands, and offices and activities across the United States, Kiadis is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at www.kiadis.com.

Forward Looking Statements

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis’ or, as appropriate, Kiadis’ officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Innate Pharma Receives Prime Designation From the European Medicines Agency for Lacutamab in Sézary Syndrome

Priority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options

MARSEILLE, France, Nov. 13, 2020 (GLOBE NEWSWIRE) — Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company“) today announced that the European Medicines Agency (EMA) has granted PRIME designation to lacutamab, the Company’s proprietary first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, for the treatment of patients with relapsed or refractory Sézary syndrome (SS) who have received at least two prior systemic therapies.

The PRIME designation is based on efficacy data in relapsed or refractory SS patients from the completed Phase 1 dose escalation and expansion trial, and is supported by safety data in SS patients from both the Phase 1 trial and ongoing Phase 2 TELLOMAK clinical trial. This is the first time PRIME designation has been granted for a potential treatment of any sub-type of T-cell lymphoma.


We are pleased that the EMA has granted PRIME designation
for
lacutamab
, as
S
é
zary
syndrome is the most aggressive form of
cutaneous T-cell lymphoma
and
patients facing advanced disease are
in
great
need of new
, targeted
treatment options,” said Joyson Karakunnel, MD, Msc, FACP, Executive Vice President and Chief Medical Officer, Innate Pharma.Lacutamab is an important asset for our Company,and this designation further validates our work to deliver this potentially first-in-class treatment to patients as quickly as possible.”

PRIME designation by the EMA supports the development of promising new medicines that target an unmet medical need. It allows for proactive support from the EMA throughout the clinical development process and enables accelerated assessment. Lacutumab was also awarded Fast Track designation by the U.S. Food and Drug Administration in 2019 for the treatment of adult patients with relapsed or refractory SS who have received at least two prior systemic therapies. 

About
S
é
zary
Syndrome
:

Sézary syndrome is the leukemic variant of cutaneous T-cell lymphoma (CTCL), a heterogeneous group of non-Hodgkin’s lymphomas which arise primarily in the skin. Patients often experience very poor quality of life with severe and debilitating pruritus (chronic itchy skin). Despite recent advancements, SS is associated with a high relapse rate with currently available therapies. 

About
Lacutamab
:

Currently in Phase 2 development, lacutamab (IPH4102) is a proprietary first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, designed for treatment of CTCL, an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few therapeutic options at advanced stages.

KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up to 85% of them with certain aggressive CTCL subtypes, in particular, SS. It has a restricted expression on normal tissues. Lacutamab was granted orphan drug designation in the European Union and in the United States for the treatment of patients with CTCL.

About
the
T
ELLOMAK
Trial:

TELLOMAK is a global, open-label, multi-cohort Phase 2 clinical trial conducted in the United States and Europe. In this clinical trial, lacutamab is being evaluated in patients with advanced t-cell lymphomas (TCL). TELLOMAK is expected to recruit up to 150 patients, with lacutamab evaluated: 

  • As a single agent in approximately 60 patients with Sézary syndrome who have received at least two prior systemic therapies, including mogamulizumab 
  • As a single agent in approximately 90 patients with mycosis fungoides (MF) who have received at least two systemic therapies 

In patients with MF, the study is designed to evaluate the benefit of lacutamab according to KIR3DL2 expression. The study comprises two cohorts in MF, testing lacutamab in KIR3DL2 expressing and non-expressing patients.  These cohorts follow a Simon 2-stage design that will terminate if treatment is considered futile. The Sézary syndrome cohort of the study could enable the registration of lacutamab in this indication. 

The primary endpoint of the trial is objective response rate. Key secondary measures include incidence of treatment emergent adverse events, quality of life, overall response rate, progression-free survival and overall survival.  

About Innate Pharma:

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has been a pioneer in the understanding of natural killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at www.innate-pharma.com

Information about Innate Pharma shares:

ISIN code

Ticker
code

LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors:

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995.The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts, the Company’s continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company’s business, financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:


Investors

Innate
Pharma        
Tel.: +33 (0)4 30 30 30 30
[email protected]


Media

Innate Pharma

Tracy Rossin (Global/US)
Tel.: +1 240 801 0076
[email protected]

ATCG Press
Marie Puvieux (France)
Tel.: +33 (0)9 81 87 46 72
innate-pharm[email protected]

 

Organogenesis Holdings Inc. Announces Pricing of Public Offering of Class A Common Stock

CANTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the pricing of an underwritten public offering of 17,500,000 shares of its Class A common stock, offered at a price to the public of $3.25 per share. The gross proceeds to Organogenesis Holdings from this offering are expected to be approximately $56.9 million, before deducting the underwriting discounts and commissions and other offering expenses payable by Organogenesis Holdings. Organogenesis Holdings has granted the underwriters a 30-day option to purchase up to an aggregate of 2,625,000 additional shares of its Class A common stock. The offering is expected to close on or about November 17, 2020, subject to customary closing conditions.

Morgan Stanley & Co. LLC and SVB Leerink LLC are acting as joint book-running managers of the offering and BTIG, LLC and Oppenheimer & Co. Inc. are acting as co-managers for the offering.

Organogenesis Holdings intends to use the net proceeds from this offering, together with other available funds, for working capital and general corporate purposes, including, but not limited to, facility expansion and manufacturing enhancements, salesforce expansion and to conduct clinical studies of, obtain regulatory approvals and additional commercial insurance coverage for its products.  The Company will retain broad discretion to allocate the proceeds.

A registration statement on Form S-1 relating to the shares of Class A common stock being offered has been filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). The offering is being made only by means of a prospectus included in the registration statement declared effective by the SEC, copies of which may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at [email protected], or SVB Leerink, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525, ext. 6132, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Organogenesis Holdings’ anticipated closing date for the sale of Class A common stock and the use of proceeds from that offering, that involve a number of risks and uncertainties. Statements that are not historical facts are based on Organogenesis Holdings’ current expectations, beliefs and assumptions regarding the market for its Class A common stock. There can be no assurance regarding the completion, timing or size of the proposed offering. Important factors that could cause actual outcomes to differ materially from those indicated by these forward-looking statements include risks and uncertainties related to market conditions, the satisfaction of customary closing conditions related to the proposed public offering and others described in Organogenesis Holdings’ registration statement on Form S-1. Organogenesis Holdings cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Organogenesis Holdings undertakes no obligations to update or revise these statements, except as may be required by law.

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.



Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
[email protected]
443-213-0500

Press and Media Inquiries:
Organogenesis
Lori Freedman
[email protected]    
781-830-2338

Topcoder Announces Winners of the 2020 Innovation Awards

Topcoder Announces Winners of the 2020 Innovation Awards

Customers, individuals recognized at Topcoder’s annual Innovation Summit

INDIANAPOLIS, Ind. & BANGALORE, India–(BUSINESS WIRE)–Topcoder, a Wipro company, and the world’s largest technology network and on-demand digital talent platform, today announced the winners of the coveted 2020 Innovation Awards through a virtual ceremony during the annual Innovation Summit. The award program celebrates customers and individuals who have done extraordinary work on the Topcoder Platform, and with the global Topcoder Community, across six categories: Cutting Edge, Enterprise Resiliency, Power User, Program of the Year, Public Sector and Wipro Partnership.

“Technology is a bridge across digital divides. It fosters an environment where people work together with all their collective passion, creativity and grit to get big things done: that’s what the Topcoder Innovation Awards are about,” said Michael P. Morris, Chief Executive Officer, Topcoder and Global Head of Crowdsourcing, Wipro Limited. “Those earning recognition are not just weathering the storm of 2020, but thriving to push technology forward to innovate beyond uncertain times. We are proud to honor these trailblazers and look forward to their continued partnership.”

As part of the summit, Topcoder provided insights into crowdsourcing, open talent models and upskilling trends across vertical markets. Highlights on Topcoder Platform advancements were included, as well. The winners in each category of the 2020 Topcoder Innovation Award are as below:

Enterprise Resiliency Award – In light of 2020’s many challenges, this award recognizes global brands that used the Topcoder Platform to persevere on unprecedented technology projects and workforce talent strategy solutions.

Telstra

Telstra leveraged the Topcoder Platform with an unyielding commitment to quality and found innovative ways to deliver solutions faster. Telstra has become a model for others in terms of workforce strategy innovation.

Power User Award – Awarded to a technology champion and Topcoder advocate that uses the Topcoder Platform to make development better, simpler, and faster.

Greg Tappert, Senior Manager, Product and Technology for T-Mobile

Greg Tappert has been an advocate for Topcoder within T-Mobile since 2018. Most recently, he led the effort to reimagine a web-based common language and process application for comprehensive, internal IT project management. An outstanding leader and team player well-respected by colleagues, Greg leveraged the Topcoder Platform and Community to design, develop, deploy, and support the application. Greg has been executing T-Mobile’s vision to expand use of Topcoder throughout other areas of development.

Cutting Edge Award – Highlights a company using the Topcoder Platform for the “project of the year,” which is unique and disruptive.

Leading Pharmaceutical Company, United States of America

For a critical and time-sensitive trial planning initiative, the company utilized the Topcoder Platform and Topcoder Data Science Community to validate a prediction model, operationalize it for use with existing data, and develop bespoke visualizations to support management of the effort, in under four weeks.

Public Sector Award – Innovative Federal organizations making a tangible difference, internally and externally, by using the Topcoder Platform and Community.

United States Bureau of Reclamation

The Bureau of Reclamation (Reclamation) has been recognized for the use of Topcoder for software development that lead to global advancement. The Reclamation Stream Flow Project pushed the envelope on forecasting techniques that affected the country. This allowed better management of water resources to support vast agricultural, commercial, and residential needs. Reclamation brought innovative problems to the Topcoder Community.

Program of the Year – Recognizes the best team and program executed at scale between Topcoder and an enterprise customer.

Wellmark

Wellmark Blue Cross and Blue Shield built one of the most innovative, fastest-growing, outcome-based crowdsourcing programs in the healthcare industry. With Topcoder, Wellmark exceled at finding and keeping a highly talented, on-demand digital workforce that complemented its technology team to increase speed, agility and quality of every aspect of software development. Crowd is a key part of Wellmark’s technology transformation initiatives aimed at raising the performance and efficiency across investments.

Wipro Partnership Award – Honors outstanding people and companies leveraging the power of Topcoder and Wipro to achieve IT innovations.

Srinivassa HG, Vice President, EMEA Digital Business Head, Wipro Limited

Srinivassa HG initiated multiple large-scale Topcoder engagements for global customers across Banking, Hospitality, Telecommunications. Srinivassa highlighted the Topcoder Platform and Community as a valuable enterprise crowdsourcing solution and championed its use in Wipro Digital’s approach to EMEA customers.

For more information on Topcoder, and these innovative winning projects, companies and individuals, visit www.topcoder.com.

About Topcoder

Topcoder, a Wipro company, is the world’s largest technology network and on-demand digital talent platform with more than 1.6 million developers, designers, data scientists and testers around the globe. Topcoder empowers organizations including Adobe, BT, Comcast, Google, Harvard, Land O’Lakes, Microsoft, NASA, SpaceNet, T-Mobile, US Department of Energy, Zurich Insurance and more, to accelerate innovation, solve challenging business problems and tap into hard-to-find technology skills. Enterprises distribute work through the Topcoder Platform where Topcoder Community members develop innovative solutions, earn money, gain experience, and achieve recognition. Topcoder became a part of Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, in November 2016.

About Wipro Limited

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading global information technology, consulting and business process services company. We harness the power of cognitive computing, hyper-automation, robotics, cloud, analytics and emerging technologies to help our clients adapt to the digital world and make them successful. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability and good corporate citizenship, we have over 180,000 dedicated employees serving clients across six continents. Together, we discover ideas and connect the dots to build a better and a bold new future.

Forward-Looking Statements

The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India, unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers’ ability or willingness to purchase our offerings, delay prospective customers’ purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf.

Media Contact:

Nisha Chandrasekaran

Wipro Limited

[email protected]

KEYWORDS: Ireland India United States United Kingdom North America Asia Pacific Europe Indiana

INDUSTRY KEYWORDS: Technology Consulting Security Other Technology Professional Services Software Networks Internet Data Management

MEDIA:

Logo
Logo

BIGG Digital Assets Inc. Announces Upsize of Previously Announced Overnight Marketed Public Offering to $6 Million

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE U.S.

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”) (CSE: BIGG; OTCQB: BBKCF; WKN: A2PS9W) is pleased to announce that, due to strong investor demand, it has increased its previously announced overnight public marketed offering to 25,000,000 units of the Company (“Units”) at a price of $0.24 per Unit for gross proceeds of approximately $6 million (the “Offering”).

The Offering is being conducted by a syndicate of underwriters led by PI Financial Corp. and including Canaccord Genuity Corp., Echelon Wealth Partners, Haywood Securities Inc. and M Partners Inc. (collectively, the “Underwriters”). The Company will shortly file an amended and restated preliminary short form prospectus (the “AR Preliminary Prospectus”) with the securities commissions in each of the provinces of Canada (other than Québec) amending and restating the preliminary short form prospectus dated November 11, 2020 to reflect the terms of the Offering. Copies of the AR Preliminary Prospectus will be available on SEDAR at www.sedar.com.

Each Unit will consist of one common share of the Company (a “Common Share”) and one-half Common Share purchase warrant (each such full warrant, a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share (a “Warrant Share”) at a price equal to $0.30 per Warrant Share for a period of 24 months following the closing of the Offering, subject to an accelerated expiry if the ten trading day volume-weighted average price of the Common Shares on the Canadian Securities Exchange (the “CSE”) is equal to or greater than $0.60 per Common Share.

The Offering is made pursuant to the terms of an underwriting agreement, as amended, with the Underwriters, which grants the Underwriters an over-allotment option to increase the size of the Offering by up to 15% of the aggregate number of Units (or the components thereof) on the same terms and conditions of the Offering (the “Over-Allotment Option”), exercisable in whole or in part at any time up to 30 days after and including the closing date of the Offering. In the event that the Over-Allotment Option is exercised in full, the aggregate gross proceeds of the Offering to the Company will be $6.9 million.

The Company intends to use the proceeds from the Offering for research and development, expansion of sales and marketing teams for Blockchain Intelligence Group internationally and Netcoins domestically, additional liquidity for Netcoins trade settlement, increase of long-term Bitcoin investment holdings, and working capital.

The Offering is expected to close on or about November 30, 2020 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the CSE.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

On behalf of Board

Mark Binns
CEO
[email protected]
T:+1.844.515.2646


The CSE does not accept responsibility for the adequacy or accuracy of this press release.

About BIGG Digital Assets Inc.

BIGG believes the future of crypto is a safe, compliant, and regulated environment. BIGG invests in products and companies to support this vision. BIGG owns two operating companies: Blockchain Intelligence Group (blockchaingroup.io) and Netcoins (netcoins.ca).

Blockchain Intelligence Group (BIG) has developed a Blockchain-agnostic search and analytics engine, QLUETM, enabling Law Enforcement, RegTech, Regulators and Government Agencies to visually track, trace and monitor cryptocurrency transactions at a forensic level. Our commercial product, BitRank Verified® , offers a “risk score” for cryptocurrencies, enabling RegTech, banks, ATMs, exchanges, and retailers to meet traditional regulatory/compliance requirements.

Netcoins develops brokerage and exchange software to make the purchase and sale of cryptocurrency easily accessible to the mass consumer and investor with a focus on compliance and safety. Netcoins utilizes BitRank Verified® software at the heart of its platform and facilitates crypto trading via a self-serve crypto brokerage portal at Netcoins.app.

For more information and to register to BIGG’s mailing list, please visit our website at https://www.biggdigitalassets.com. Or visit SEDAR at www.sedar.com.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements regarding the ability of the Company to close the Offering, the anticipated terms of the Offering, the anticipated use of proceeds from the Offering, the proposed timing of the Offering, and the Company’s beliefs about the future of crypto are “forward-looking statements”. Forward-looking information can be identified by the use of words such as “will” or “believe” or variations of such words or statements that certain actions, events or results “will” be taken, occur or be achieved. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, estimates, forecasts, projections and other forward-looking statements will not occur. These assumptions, risks and uncertainties include, among other things, the state of the economy in general and capital markets in particular, and other factors, many of which are beyond the control of BIGG. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. Undue reliance should not be placed on the forward-looking information because BIGG can give no assurance that they will prove to be correct. Important factors that could cause actual results to differ materially from BIGG’s expectations include, consumer sentiment towards BIGG’s products and Blockchain technology generally, technology failures, competition, and failure of counterparties to perform their contractual obligations.

The forward-looking statements contained in this press release are made as of the date of this press release. Except as required by law, BIGG disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, BIGG undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.